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Phthalates are synthetic chemicals used in plas-
tics, personal care products, and building mate-
rials. Phthalates are metabolized and excreted 
in urine 12–48 hr after exposure (Koch et al. 
2005). Urinary phthalate metabolites measured 
have been used extensively as biomarkers of 
human exposure (Hauser and Calafat 2005).
The metabolites of at least four phthalates 
can induce a wide range of responses with 
potential relevance to human reproduction 
and development (Hauser and Calafat 2005; 
Swan 2008). When given to rats in utero, 
di(2-ethylhexyl) phthalate (DEHP), di-n-bu-
tyl phthalate (DnBP), diisobutyl phthalate 
(DiBP), and butylbenzyl phthalate (BBzP) 
altered steroidogenesis and produced a pheno-
type that involved reduced testosterone syn-
thesis in fetal Leydig cells and concomitant 
effects on the male offspring resembling the 
testicular dysgenesis syndrome (Barlow et al. 
2003; Ema et al. 2000; Mylchreest et al. 2000; 
Saillenfait et al. 2008; Sharpe 2001). Similarly, 
in female rats, DEHP, DnBP, and DiBP pro-
duced alterations in ovarian steroidogenesis, 
partly mediated by CYP19 (aromatase) inhibi-
tion and progesterone inhibition (Boberg et al. 
2008; Davis et al. 1994a, 1994b; Lovekamp 
and Davis 2001).
The peroxisome proliferator–activated 
receptor protein gamma (PPARγ) is a master 
regulator of several reproductive and develop-
mental pathways, including steroidogenesis, 
differentiation, fatty acid uptake and trans-
port, and inflammation related to parturition 
(Froment et al. 2006; Schaiff et al. 2006). 
PPARγ is expressed in the human tropho-
blast and is essential to basic placental devel-
opment and function (Fournier et al. 2007). 
Agonism of PPARγ by phthalate metabolites 
has been proposed as a mechanism of action 
(Lovekamp-Swan et al. 2003; Maloney and 
Waxman 1999). In vivo prenatal exposure to 
a metabolite of DEHP resulted in dose-depen-
dent activation of PPARγ in rat placenta and 
changes in the expression of its downstream 
targets, including fatty acid transport protein 
and cytochrome oxidase-2 (Xu et al. 2008).
Prenatal exposure to DEHP has been asso-
ciated with the timing of labor in four different 
cohorts, suggesting phthalate-related disrup-
tion in placental function (Adibi et al. 2009a; 
Latini et al. 2003; Whyatt et al. 2009; Wolff 
et al. 2008). We hypothesized that phthalate 
exposure could also be associated with altera-
tions in human placental development and 
function, through PPARγ-mediated pathways 
(e.g., trophoblast differentiation).
We selected specific gene targets unified 
in two pathways based on their strong asso-
ciation with placental health and function and 
direct experimental evidence of their disrup-
tion by DEHP, DnBP, DiBP, or BBzP. Our 
criteria included targets downstream of those 
disrupted by phthalates and/or hypothesized 
to be disrupted by phthalates given their 
known interactions with structurally similar 
compounds (Schaiff et al. 2006). For ste-
roidogenesis, target genes included CYP19, 
P450 cholesterol side chain cleavage enzyme 
(P450scc), 17β-hydroxysteroid dehydrogenase 
type 1 (17β-HSD), and cytochrome P450 
1B1 (CYP1B1). For trophoblast differentia-
tion, target genes included PPARγ, human 
chorionic gonadotropin (HCG), and the aryl 
hydrocarbon receptor (AhR).
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Ba c k g r o u n d: Phthalates can alter steroidogenesis and peroxisome proliferator–activated receptor 
gamma (PPARγ)–mediated transcription in rodent tissues. The placenta offers a rich source of bio-
markers to study these relationships in humans.
oB j e c t i v e: We evaluated whether gestational phthalate exposures in humans were associated with 
altered human placental steroidogenesis and trophoblast differentiation as measured by markers of 
mRNA transcription.
Me t h o d s : We measured seven target genes in placentas collected from 54 Dominican and African-
American women at delivery in New York City using quantitative real-time polymerase chain reac-
tion (qPCR), normalized to 18S rRNA. qPCR results for the target genes were log-transformed, 
converted to Z-scores, and grouped into two functional pathways: steroidogenesis (aromatase, 
cholesterol side chain cleavage enzyme, 17β-hydroxysteroid dehydrogenase type 1, and cytochrome 
P450 1B1) and trophoblast differentiation (PPARγ, aryl hydrocarbon receptor, and human chori-
onic gonadotropin). Repeated measures models were used to evaluate the association of phthalate 
metabolites measured in third-trimester urine samples with each group of target genes, accounting 
for correlation among the genes within a pathway.
re s u l t s: Higher urinary concentrations of five phthalate metabolites were associated with lower 
expression of the target genes reflecting trophoblast differentiation. Results were less consistent for 
genes in the steroidogenesis pathway and suggested a nonlinear dose–response pattern for some 
phthalate metabolites.
co n c l u s i o n s: We observed a significant association between prenatal exposure to phthalates and 
placental gene expression within two pathways. Further studies are warranted to understand the 
significance of this association with respect to fetal development and placental function.
key w o r d s : epidemiology, gene expression, phthalates, placenta, pregnancy, prenatal, steroido-
genesis, trophoblast differentiation. Environ Health Perspect 118:291–296 (2010).  doi:10.1289/
ehp.0900788 available via http://dx.doi.org/ [Online 15 September 2009]Adibi et al.
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Materials and Methods
Study participants. Fifty-four of 148 partici-
pants in the Columbia Center for Children’s 
Environmental Health (CCCEH) with pla-
centas collected at delivery between May 
2002 and June 2005 and with both maternal 
urine samples and medical record data were 
included this study. Placentas were sampled 
from 70% (148 of 211) of the 211 CCCEH 
births over this time; the remainder could not 
be obtained because of lack of notification 
of labor onset and other logistical obstacles. 
CCCEH participants were enrolled through 
the prenatal clinics at New York Presbyterian 
and Harlem Hospital Centers in New York 
City. To be eligible, the woman had to reside 
in the study area for at least 1 year, receive 
her first prenatal visit by the 20th week of 
pregnancy, and be free of diabetes, hyperten-
sion, and known HIV and drug or alcohol 
abuse (Perera et al. 2006; Whyatt et al. 2003). 
The institutional review boards of Columbia 
University, the Centers for Disease Control 
and Prevention (CDC), and the Harvard 
School of Public Health Human Subjects 
Committee approved the CCCEH study and 
substudies. Written informed consent was 
obtained from all study participants.
Placenta sampling. The 54 placentas were 
sampled between 4 min and 2 hr after deliv-
ery. Samples of chorionic villi were taken on 
the fetal side of the placenta. One sample was 
taken from the inner region proximal to the 
umbilical cord insertion point, and one from 
the outer region closer to the edge, yielding 
two samples per placenta. Methods and ratio-
nale for the sampling scheme are described 
in detail elsewhere (Adibi et al. 2009b). We 
attempted to control for within-placenta 
variability by collecting one sample from 
the inner and one from the outer region of 
each placenta. Care was taken in dissection to 
maximize the amount of villous tissue in the 
sample and to avoid membrane contamina-
tion as well as decidua contamination. Samples 
were preserved in RNAlater (Ambion, Austin, 
TX) to stabilize the RNA and stored at –80°C.
RNA analysis. Total RNA was isolated 
from approximately 300 mg of tissue using 
the RNeasy Midi Kit (Qiagen, Valencia, CA). 
Genomic DNA contamination in the sample 
was minimized with a DNase digestion step 
(Rozen and Skaletsky 2000). Total RNA was 
measured by determining absorbance at 260 
nm using an Ultrospec 2100 pro ultraviolet/
visible spectrophotometer (GE Healthcare, 
Piscataway, NJ). RNA purity was assessed by 
the ratio of absorption at 260 nm to 280 nm 
and visually by agarose gel electrophoresis. 
Approximately 3 µg total RNA was used in a 
reverse transcription (RT) reaction to synthe-
size cDNA using the SuperScript First-Strand 
Synthesis System from Invitrogen (Carlsbad, 
CA). Finally, quantitative real-time polymerase 
chain reaction (qPCR) was used to quantitate 
mRNA levels in each sample for individual 
genes. Ribosomal RNA from 18S was selected 
as a housekeeping gene to serve as an inter-
nal control for quantity and quality of cDNA 
going into the RT reaction, based on the results 
of a previous analysis (Adibi et al. 2009b). All 
samples were analyzed using the ABI Prism 
7500 Sequence Detection System (Applied 
Biosystems, Foster City, CA). Cycling condi-
tions were the same for seven transcripts (18S, 
CYP19, PPARγ, AhR, CYP1B1, 17β-HSD, 
HCG): 95.0°C for 5 min for activation of the 
enzyme, 95.0°C for 30 sec for denaturation 
and 60.0°C for 1 min for annealing/extension 
for 40 cycles, followed by a dissociation step. 
Cycling conditions for P450scc were the same 
except the annealing/extension was carried out 
at 55.0°C for 1 min. Forward and reverse prim-
ers (Sigma, St. Louis, MO) were either designed 
by Primer3 (Rozen and Skaletsky 2000) or 
selected from the literature and referenced by 
a PubMed Identifier (PMID; Table 1). Each 
reaction used 2 µL or 90 ng cDNA assuming 
90% efficiency of the cDNA synthesis reac-
tion, forward and reverse primers at optimized 
concentrations, and SYBR Green PCR Master 
Mix kit (Applied Biosystems, Foster City, CA) 
for a total reaction volume of 25 µL.
Specificity and quantitation. Each sam-
ple was run in duplicate, and values not fall-
ing within 50% of their mean were rerun. 
Specificity of the PCR product was evaluated 
using the melting curve generated at the end 
of amplification and by running a 2% agarose 
gel to visualize the PCR product. Absolute 
quantitation of mRNA concentration in the 
original sample was achieved using a standard 
curve generated for each batch. Each standard 
curve included two nontemplate controls and 
eight serial dilutions covering the range of 103 
to 107 molecules/µL. The standards for each 
gene were prepared as described previously 
(Bhat and Epelboym 2004). The R2 for the 
standard curve was between 0.98 and 1.00; the 
plate was rerun if it was < 0.95. The ratio of 
target gene mRNA molecules to 18S mRNA 
molecules was calculated for each.
Phthalate metabolite measurements. 
Maternal urine samples, collected in the early 
third trimester (n = 54), were analyzed for the 
four DEHP metabolites mono(2-ethylhexyl) 
phthalate (MEHP), mono(2-ethyl-5-oxohexyl) 
phthalate (MEOHP), mono(2-ethyl-5-hydroxy-
hexyl) phthalate (MEHHP), and mono-2-ethyl-
5-carboxypentyl phthalate (MECPP); the DnBP 
metabolite mono-n-butyl phthalate (MnBP); 
the DiBP metabolite monoisobutyl phthalate 
(MiBP); and the BBzP metabolite monobenzyl 
phthalate (MBzP) at the CDC. Because of the 
high correlations among MEOHP, MEHHP, 
and MECPP (Spearman correlation r  = 
0.96–0.98), we limited our analysis to MEOHP. 
To represent total DEHP urinary concentra-
tion, we summed the four DEHP metabolites 
(MEHP, MEOHP, MEHHP, MECPP) in 
nanomoles per liter (ΣDEHP).
The analytical approach involved enzymatic 
deconjugation of the phthalate metabolites 
from their glucuronidated form, solid-phase 
extraction, separation with high-performance 
liquid chromatography, and detection by iso-
tope-dilution tandem mass spectrometry (Kato 
et al. 2005). To monitor for accuracy and preci-
sion, each analytical run included the unknown 
samples together with calibration standards, 
reagent blanks, and quality control materials 
of high and low concentration. The limits of 
detection (LODs) were (in nanograms per mil-
liliter) MEHP, 0.9; MEOHP, 0.45; MEHHP, 
0.32; MECPP, 0.25; MiBP, 0.26; MnBP, 0.40; 
and MBzP, 0.11. Concentrations below the 
LOD were set to one-half the LOD for statisti-
cal analysis. Specific gravity was measured at 
CDC using a PAL 10-S hand-held refractome-
ter (Atago, Bellevue, WA). Urinary concentra-
tions were adjusted for specific gravity using a 
modification of the formula by Hauser et al. 
(2004): Pc = P × [(1.016 – 1)/(SG – 1)], where 
Pc is the specific-gravity–corrected phthalate 
Table 1. Primer sets for qPCR analysis.
Gene Direction Primer sequence Base pairs Reference
CYP19 Forward ATACCAGGTCCTGGCTACTG 249 PMID 11745463a
Reverse TCTCATGCATACCGATGCACTG
PPARγ Forward GCTGTGCAGGAGATCACAGA 225 Designed in Primer3
Reverse GGGCTCCATAAAGTCACCAA
AhR  Forward ACATCACCTACGCCAGTCGC 101 PMID 12520072b
Reverse TCTATGCCGCTTGGAAGGAT
CYP1B1 Forward ACCGTTTTCCGCGAATTC 196 PMID 12040753c
Reverse GTACGTTCTCCAAATCCAGCC
P450scc Forward CCTGCAGTGGCACTTGTATG 418 PMID 11997174d
Reverse GGTCATCTCTAGCTCAGCGA
17β-HSD type 1 Forward GCCGCGTGGACGTGCTGGTGTGTAAC 201 PMID 12242730e
Reverse CCATCAATCCTCCCACGCTCCCGG
HCG Forward TCCCACTCCACTAAGGTCCAA 106 PMID 15081642f
Reverse CCCCATTACTGTGACCCTGTT
18S rRNA Forward CGGCTACCACATCCAAGGAA 187 PMID 14583453g
Reverse GCTGGAATTACCGCGGCT
aMiyoshi et al. 2001. bLin et al. 2003. cNishimura et al. 2002. dYu et al. 2002. eKoh et al. 2002. fPidoux et al. 2004. gVissac-
Sabatier et al. 2003.Prenatal phthalates and placental gene expression
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concentration, P is the observed phthalate con-
centration, and SG is the specific gravity of the 
urine samples.
Statistical analysis. Gene expression values 
and phthalate metabolite concentrations were 
log transformed to approximate a normal dis-
tribution. Z-scores were calculated individually 
for each gene to put them on the same scale. 
The Z-score, also called the standard score, uses 
the population mean and standard deviation 
to standardize or normalize sample values so 
that they share a common underlying distri-
bution. Z-scores were modeled in two groups 
by functional pathways, steroidogenesis and 
trophoblast differentiation. Spearman correla-
tion coefficients were used to estimate pairwise 
associations among gene transcripts. Variance 
component analysis was used to evaluate 
between- versus within-placenta variability.
Multivariate mixed effects models were used 
to estimate associations between gene expres-
sion and specific gravity–adjusted phthalate 
metabolite concentrations (Fitzmaurice et al. 
2004; Verbeke and Molenberghs 2000). Gene 
expression Z-scores for multiple genes within 
a pathway were modeled as a correlated vec-
tor of eight responses within each placenta for 
the steroidogenesis pathway (i.e., two samples 
per placenta and four target genes measured 
on each sample) and six responses for tropho-
blast differentiation (i.e., two samples per pla-
centa and three target genes measured on each 
sample) as a function of phthalate concentra-
tions and other covariates. The mixed effect 
model approach allows for the analysis of the 
expression of each gene separately while taking 
into account differences between genes within 
a pathway, and simultaneously adjusting for the 
correlation between the two samples and three 
to four target genes measured on a single pla-
centa. We assumed equal correlation between 
any two responses measured within a single 
placenta. We grouped the gene transcripts by 
pathway to most efficiently use information 
collected from each placenta and to increase 
our statistical power to detect associations 
with phthalate exposures. Urinary phthalate 
concentrations were considered both as log-
transformed continuous measures (assuming 
linearity of dose response) and as grouped into 
quintiles to avoid the assumption of linearity. 
We used the fitted mixed effect model to calcu-
late the predicted mean Z-scores and standard 
errors for each quintile of phthalate exposure, in 
order to illustrate dose–response relationships. 
The assumption that the dose–response pattern 
was the same across all target genes within a 
pathway was assessed by including additional 
interaction terms between type of gene and 
quintile of exposure; tests of interactions signifi-
cant at p < 0.05 suggest a lack of agreement in 
dose–response patterns.
We evaluated model fit and potential con-
founding by sampling characteristics and other 
variables (season, demographic characteristics, 
maternal size and adiposity, smoking status, 
maternal health, pregnancy history, and fetal 
sex). Covariates other than specific-gravity–
adjusted phthalate exposure levels and gene 
(categorical variable with a level for each gene 
in pathway) were retained in the model if sig-
nificant at p < 0.05. In our final models, we 
controlled for qPCR plate, season of delivery, 
and level of education. In the steroidogenesis 
models, we also controlled for year of deliv-
ery. In the trophoblast differentiation model, 
we also controlled for mother’s ethnicity, net 
weight gain, and history of hypertension. 
Statistical significance was defined by a (two-
sided) p-value ≤ 0.05. SAS version 9.1 (SAS 
Institute Inc., Cary, NC) software was used to 
conduct all analyses.
Results
The 54 women included in our study were a 
subset of CCCEH participants similar demo-
graphically to those in the parent study except 
with a larger proportion of Dominican women 
(83% vs. 74%) and a higher percentage of par-
ticipants with a high school degree or GED 
(65% vs. 37%) (Table 2). The distributions of 
the urinary phthalate metabolites were similar 
to those reported in a larger sample from the 
same cohort (Table 3) (Adibi et al. 2008).
The median yield of total RNA per placenta 
biopsy was 62 µg (mean ± SE = 72 ± 5 µg). 
Analytic gels showed two distinct bands at 
18S and 28S with minimal signs of degrada-
tion. Of the 108 biopsies from 54 placentas, 
two samples had insufficient RNA/cDNA 
at the time of qPCR analysis for HCG, and 
one for 17β-HSD. One RNA/cDNA sam-
ple was missing at the time of analysis of 18S 
(housekeeping gene), which is the reason for 
the single missing value across all remaining 
transcripts (Table 4). The ranking of tran-
scripts by median message level (mRNA/3 µg 
total RNA) was as follows: 18S rRNA (9.80 × 
105), HCG (4.30 × 105), P450scc (3.94 × 104), 
CYP19 (3.30 × 104), 17β-HSD (7.47 × 103), 
PPARγ (3.56 × 103), AhR (5.03 × 102), and 
CYP1B1 (1.02 × 102).
Between-placenta variability was higher 
than within-placenta variability for CYP19 
(62% vs. 38%) and AhR (59% vs. 42%). 
For four other transcripts, the between-pla-
centa variability was slightly lower than 50% 
(PPARγ, 47%; P450scc, 40%; 17β-HSD, 41%; 
HCG, 46%), and was 30% for CYP1B1. This 
was consistent with our previous analysis that 
demonstrated high within-placenta variability, 
which was mitigated by controlling for location 
within the chorionic plate (Adibi et al. 2009b). 
Transcripts were significantly correlated within 
the pathway groupings (Table 4).
We fitted mixed effects models both with 
and without the assumption of linearity of 
phthalate exposure effects to evaluate associa-
tions with gene expression levels within each 
pathway (Tables 5 and 6). In the case of 
Table 2. CCCEH sample characteristics (n = 54).
Characteristic Value
Gestational age (weeks)a 39.5 ± 1.6
Birth weight (g)b 3,324 ± 466
Maternal age (years) 26.1 ± 4.5
Gestational agea
< 37 weeks 3 (6)
37–41 weeks 45 (88)
> 41 weeks 3 (6)
Race/ethnicity
Dominican 45 (83)
African American 9 (17)
Marital status
Never married 35 (65)
Widowed, divorced, separated 4 (7)
Married 15 (28)
Education
Less than high school 6 (11)
High school or GED 35 (65)
More than high school 13 (24)
Parity
0 live births 21 (39)
1 live birth 19 (35)
> 1 live births 14 (26)
Cesarean sectionc 14 (27)
Body mass indexd
≤ 24.9 29 (54)
> 24.9 and ≤ 29.9 12 (22)
> 29.9 10 (19)
Female sex, newborn (%) 26 (48)
Season
Summer 13 (24)
Fall 8 (15)
Winter 17 (31)
Spring 16 (30)
Year of delivery
2002 8 (15)
2003 13 (24)
2004 14 (26)
2005 19 (35)
Values are mean ± SD or no. (%).
aThree missing for gestational age. bThree missing for 
birth weight. cTwo missing for delivery method. dThree 
missing for body mass index.
Table 3. Distribution of maternal urinary phthalate metabolites (ng/mL; n = 54).
Measure MEHP MEOHP
ΣDEHP 
metabolitesa MnBP MiBP MBzP
Geometric mean 5.5 16.5 279.8 34.6 10.4 20.4
Quintiles, specific-gravity adjusted
Quintile 1 ≤ 2.2  ≤ 10.2  ≤ 112.2  ≤ 19.6  ≤ 6.2  ≤ 5.7
Quintile 2 2.3–4.8 10.3–15.0 112.3–221.1 19.7–37.9 6.3–11.1 5.8–15.7
Quintile 3 4.9–9.6 15.1–26.0 221.2–371.5 38.0–52.8 11.2–14.1 15.8–32.1
Quintile 4  9.7–18.8 26.1–47.5 371.6–735.2 52.9–73.0 14.2–24.4 32.2–88.9
Quintile 5 > 18.8 > 47.5 > 735.2 > 73.0 > 24.4 > 88.9
aSum of MEHP, MEOHP, MEHHP, and MECPP, in nanomoles/liter.Adibi et al.
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steroidogenesis, we found no significant associa-
tions of the phthalate metabolite levels with tar-
get genes in the models using log concentration 
levels (i.e., assuming linearity) (Table 5). We 
found a significant difference across quintiles of 
MnBP exposure (p = 0.001) (Table 6), with a 
trend toward a U-shaped dose–response pattern 
(Figure 1C). The Pearson correlation between 
the Z-score and the log-transformed gene 
expression value (ratio of target gene to 18S 
RNA) was 1.00. Even though Z-scores are not 
typically used in the presentation of qPCR data, 
they should be interpreted as a direct proxy for 
the mRNA levels measured in the sample.
For the trophoblast differentiation 
  pathway, higher levels of urinary metabolite 
concentrations were associated with signifi-
cantly lower levels of gene expression for all five 
phthalate metabolites and ΣDEHP (Table 5). 
We also observed differences in gene expres-
sion across the quintiles of exposure for all 
metabolites except MEHP (Table 6, Figure 2). 
Although the trend was generally inverse, there 
was a suggestion of a U-shaped curve for all 
metabolites (Figure 2).
For most phthalate metabolites, additional 
tests of interaction between individual gene 
and metabolite levels were not significant and 
thus supported the assumption of a similar 
pattern of dose response for genes within the 
same pathway. That is, the shift in Z-scores for 
each quintile of exposure level did not depend 
on which of the genes we measured. However, 
there were isolated exceptions. For the steroido-
genesis pathway, we found a significant differ-
ence in dose–response patterns of target genes 
across levels of MnBP exposure (p = 0.03). For 
the trophoblast pathway, we found a difference 
in dose–response patterns across target genes 
for MnBP (p = 0.03) and MBzP (p = 0.01; see 
Figure 2C,D).
Discussion
In a sample of 54 Dominican and African-
American women in New York City, urinary 
phthalate metabolite concentrations were 
associated with placental biomarkers of gene 
expression in two pathways, steroidogenesis 
and trophoblast differentiation.
The consistent decreases in placental gene 
expression at the higher quintile concentra-
tions of phthalate metabolites may mean that 
effects are concentrated at the higher doses or 
that women in the upper exposure quintiles are 
more susceptible to placental insults for other 
reasons that are correlated with phthalate expo-
sures that we were unable to control for. This 
cohort, which is characterized by low income 
and high social disadvantage, has significantly 
higher urinary concentrations of DnBP and 
DiBP metabolites compared with other preg-
nant women in the U.S. general population and 
in another U.S. multicenter pregnancy cohort 
(Adibi et al. 2009a). Given that high exposures 
to chemicals may be accompanied by poor 
nutrition and co-exposures to other chemicals 
and other physical and psychosocial stress, these 
women and their fetuses may be in an especially 
high category of risk (Rauh et al. 2004).
Results differed slightly when we applied 
modeling strategies that assume linearity in 
the dose response versus those that do not. 
Inspection of the associations by level of expo-
sure shows little evidence of linearity with most 
of the metabolites. Dose–response relationships 
within these pathways may be nonmonotonic, 
which would be expected given the nature of 
transcriptional regulation of nuclear receptors 
and endocrine signals and specifically with 
regard to the behavior of phthalates and other 
endocrine-disrupting compounds (Andrade et al. 
2006; Li et al. 2007; Welshons et al. 2003).
Table 5. Associations between pathway-specific placental gene expression and maternal urinary phtha-
late metabolites adjusted for specific gravity (log-transformed), using a linear model approach. 
β-Coefficient (SE), p-value
Phthalate metabolite
Steroidogenesis:  
CYP19, 17β-HSD, P450scc, CYP1B1a
Trophoblast differentiation: 
PPARγ, AhR, HCGb
MEHP 0.01 (0.12), p = 0.90 –0.15 (0.06), p = 0.02 
MEOHP –0.04 (0.13), p = 0.74 –0.28 (0.06), p < 0.0001
ΣDEHP metabolitesc –0.01 (0.13), p = 0.96 –0.19 (0.08), p = 0.03
MnBP –0.19 (0.16), p = 0.25 –0.16 (0.08), p = 0.05
MiBP –0.11 (0.14), p = 0.46 –0.21 (0.09), p = 0.02
MBzP 0.03 (0.09), p = 0.78 –0.14 (0.06), p = 0.02
an = 54, adjusted for gene, qPCR batch (CYP1B1), year of delivery, season of delivery, and level of education. bn = 54, 
adjusted for gene, qPCR batch (AhR, PPARγ), season of delivery, level of education, net weight gain, mother’s ethnicity, 
and history of hypertension. cThe square root of specific gravity was included as an independent term in the model.
Table 6. Associations between pathway-specific placental gene expression and maternal urinary phthalate metabolites, using a quintile model approach.
β-Coefficient (SE), p-value
Steroidogenesis: CYP19, 17β-HSD, P450scc, CYP1B1a Trophoblast differentiation: PPARγ, AhR, HCGb
Phthalate metabolite Quintile 2  Quintile 3 Quintile 4 Quintile 5 p-Valuec Quintile 2 Quintile 3 Quintile 4 Quintile 5 p-Valuec
MEHP 0.26 (0.35) –0.28 (0.47) –0.13 (0.43) 0.30 (0.42) 0.29 0.02 (0.29) –0.15 (0.26) –0.58 (0.30) –0.43 (0.26) 0.22
MEOHP –0.50 (0.38) –0.34 (0.28) –0.95 (0.43)* –0.03 (0.39) 0.06 –0.59 (0.31) –0.18 (0.24) –0.92 (0.25)** –0.83 (0.23)** 0.002
ΣDEHP metabolitesd –0.36 (0.36) 0.03 (0.42) –0.40 (0.41) –0.01 (0.47) 0.54 –0.13 (0.30) –0.90 (0.33)* –0.90 (0.28)** –0.92 (0.27)** 0.02
MnBP 0.72 (0.39) 0.48 (0.46) 0.83 (0.38)* –0.61 (0.41) 0.001 0.07 (0.29) –0.52 (0.26)* 0.33 (0.28) 0.57 (0.21)** 0.004
MiBP 0.14 (0.53) 0.35 (0.61) –0.18 (0.45) –0.22 (0.44) 0.71 0.43 (0.24) 0.19 (0.36) –0.92 (0.20)** –0.44 (0.23) 0.0002
MBzP 0.14 (0.49) 0.09 (0.42) –0.14 (0.43) 0.12 (0.35) 0.89 0.04 (0.30) –0.52 (0.27) –0.67 (0.24)** –0.42 (0.26) 0.01
an = 54, adjusted for gene, qPCR batch (CYP1B1), year of delivery, season of delivery, and level of education. bn = 54, adjusted for gene, qPCR batch (AhR, PPARγ), season of delivery, 
level of education, net weight gain, mother’s ethnicity, and history of hypertension. cThe type 3 test of fixed effects, a four degrees of freedom test of whether there is any difference 
among the 5 groups. Quintile 1 is the referent group. dThe square root of specific gravity was included as an independent term in the model. *p ≤ 0.05, **p ≤ 0.01; quintile 1 is the refer-
ent group in the regression models.
Table 4. Mean values of log-transformed gene transcripts and their corresponding mean Z-scores and 
Spearman correlations (95% confidence interval) between placental mRNA levels, adjusted for 18S 
mRNA, grouped by common pathway (n = 54 placentas).
Gene transcript
Measure CYP19a 17β-HSDb P450scca CYP1B1b
Steroidogenesis pathway
Mean ± SD, log transformed –3.4 ± 3.3 –4.2 ± 1.6 –2.4 ± 2.0 –8.4 ± 1.6
Mean Z-score ± SD 0.01 ± 1.1 –0.02 ± 1.2 –0.01 ± 1.2 –0.02 ± 1.2
Spearman correlation (95% CI)
CYP19 1.00 0.75 (0.65–0.82) 0.85 (0.79–0.90) 0.62 (0.49–0.72)
17β-HSD 1.00 0.87 (0.81–0.91) 0.69 (0.57–0.78)
P450scc 1.00 0.63 (0.50–0.73)
PPARγa AhRa HCGb
Trophoblast differentiation pathway
Mean ± SD, log transformed –5.3 ± 2.1 –7.1 ± 2.5 –0.9 ± 2.7
Mean Z-score ± SD –0.04 ± 1.1 0.02 ± 1.1 0.01 ± 1.1
Spearman correlation (95% CI)
PPARγ 1.00 0.41 (0.24–0.56) 0.83 (0.75–0.88)
AhR 1.00 0.68 (0.56–0.77)
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There is no consensus on the molecular 
mechanism of phthalate actions, especially 
with regard to the steroidogenic effects (Feige 
et al. 2007; Hallmark et al. 2007; Wilson et al. 
2004). Some data show effects at the level of 
mRNA transcription that are consistent with 
protein levels (Lovekamp and Davis 2001; 
McKinnell et al. 2005; Wilson et al. 2004), 
whereas others show effects at the level of pro-
tein expression but not transcription (Boberg 
et al. 2008; Lambrot et al. 2009). Attempts 
to recapitulate the steroidogenic effects of 
MEHP and MnBP in rodents using human 
testis explants have produced conflicting results 
(Hallmark et al. 2007; Lambrot et al. 2009), 
which could be due to differences in experi-
mental systems and/or species. The associa-
tion that we measured between phthalates and 
placental steroidogenesis was present only in 
the quintile models with MnBP. Interestingly, 
there is some evidence in humans that fetal tes-
ticular steroidogenesis and placental steroido-
genesis may be linked (Akre et al. 2008).
The trophoblast differentiation pathway 
(PPARγ, HCG, AhR) was of interest to us as a 
well-studied PPARγ-mediated pathway in the 
human placenta (Tarrade et al. 2001). In fact, 
HCG is a marker of syncytium formation and is 
used as an indicator of placental function in clin-
ical tests (Lepage et al. 2003; Yang et al. 2003). 
Beyond its role in xenobiotic metabolism, 
AhR is also believed to be a regulator of estro-
gen metabolism, vascularization, and hypoxic 
responses in the placenta (Detmar et al. 2008; 
Huuskonen et al. 2008). Trophoblast differ-
entiation is most important early in pregnancy 
when the placenta is initially being constructed 
and assuming its spatial and physiologic ori-
entation with respect to the fetus. Throughout 
pregnancy, a population of progenitor tropho-
blasts persists and undergoes renewal and dif-
ferentiation (Tarrade et al. 2001). Toward late 
pregnancy, there is a shift toward higher propor-
tions of syncytiotrophoblasts where PPARγ is 
localized (Borel et al. 2008; Rodie et al. 2005). 
Our ability to detect an association between 
phthalate metabolite urinary concentrations 
and trophoblast differentiation could mean that 
there was a disruption of this late-stage process. 
There may also have been effects on trophoblast 
differentiation and placental development early 
in pregnancy that were mirrored in these bio-
markers meas  ured at term. 
It is difficult to draw conclusions with a 
limited set of gene targets per pathway. These 
targets and their relationship to phthalate 
metabolites should be pursued further by 
including additional gene targets and post-
transcriptional markers. Nonetheless, corre-
lations of maternal and fetal exposures with 
transcription may provide valuable informa-
tion even if it is not possible to extrapolate to 
posttranscriptional phenotype. In most cases, 
our assumption that genes within a pathway 
were expressed in a parallel dose response was 
supported by the data.
In summary, we applied biomarkers of 
mRNA transcription in human placental tissue 
to test hypotheses on the association of prena-
tal phthalate exposure with placental develop-
ment and function. Metabolites of DEHP, 
DnBP, DiBP, and BBzP were significantly 
Figure 1. Quintile plots of estimated mean Z-scores (± SE) of gene transcripts in the placental steroido-
genesis pathway in relation to maternal urinary concentrations of MEHP (A), MEOHP (B), MnBP (C), and 
MBzP (D). C depicts a significant association between MnBP quintiles and steroidogenic gene expression 
(p = 0.001) and significantly different slopes among genes in relation to MnBP (p = 0.03). 
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Figure 2. Quintile plots of estimated mean Z-scores (± SE) of gene transcripts in the trophoblast differentia-
tion pathway in relation to maternal urinary concentrations of MEHP (A), MEOHP (B), MnBP (C), and MBzP 
(D). B–D depict significant associations between MEOHP (p = 0.002), MnBP (p = 0.004), and MBzP (p = 0.01) 
quintiles and gene expression; C and D depict significantly different slopes among genes in relation to 
MnBP (p = 0.03) and MBzP (p = 0.01).
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associated with the joint expression of three 
gene targets known to be involved in tropho-
blast differentiation (PPARγ, AhR, HCG). 
These associations were robust to linear and 
nonlinear modeling strategies and to adjust-
ment for urinary dilution. We did not detect 
robust associations of phthalate metabolites 
with the joint expression of four gene tar-
gets in the steroidogenic pathway (CYP19, 
17β-HSD, P450scc, CYP1B1). This may sug-
gest a null association of phthalates with pla-
cental steroidogenesis, or it may suggest lack 
of sensitivity in our methodology. It may also 
indicate that the model of phthalate-induced 
perturbation of steroidogenesis well described 
in rodent models cannot be directly translated 
to humans. In either case, we offer a novel 
approach to study the effects of endocrine-
disrupting compounds on placental function.
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